YM598
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hormone-Refractory Prostate Cancer
Conditions
Hormone-Refractory Prostate Cancer, Prostatic Neoplasms
Trial Timeline
— → Jun 1, 2004
NCT ID
NCT00048659About YM598
YM598 is a phase 2 stage product being developed by Astellas Pharma for Hormone-Refractory Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00048659. Target conditions include Hormone-Refractory Prostate Cancer, Prostatic Neoplasms.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00050297 | Phase 2 | Terminated |
| NCT00048659 | Phase 2 | Terminated |
Competing Products
8 competing products in Hormone-Refractory Prostate Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Zoledronic acid + Estramustine + Docetaxel | Novartis | Phase 2 | 52 |
| amg 162 | Amgen | Phase 3 | 76 |
| Denosumab | Amgen | Phase 3 | 76 |
| IV Bisphosphonate q 4 weeks | Amgen | Phase 2 | 51 |
| Dasatinib | Bristol Myers Squibb | Phase 2 | 51 |
| ILX651 | Sanofi | Phase 2 | 51 |
| VIR-5500 | Vir Biotechnology | Phase 1 | 28 |